Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Hematology/Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Oligometastases.J Clin Oncol. 1995; 13: 8-10
- Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients.Ann Surg. 2008; 247: 125-135
- Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases.Ann Surg. 1999; 230 ([discussion: 318–21]): 309-318
- Liver resection for metastatic colorectal cancer in the presence of extrahepatic disease.Ann Surg Oncol. 2009; 16: 2411-2421
- Resection of liver metastases from a noncolorectal primary: indications and results based on 147 monocentric patients.J Am Coll Surg. 1998; 187: 487-493
- Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients.Ann Surg. 2009; 250: 440-448
- Survival after pulmonary metastasectomy in soft tissue sarcoma. Prognostic factors in 214 patients.Acta Orthop Scand. 1995; 66: 561-568
- A 10-year single-center experience on 708 lung metastasectomies: the evidence of the "international registry of lung metastases.J Thorac Oncol. 2011; 6: 1373-1378
- Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma.J Thorac Cardiovasc Surg. 2007; 133: 104-110
- Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases.J Thorac Cardiovasc Surg. 1997; 113: 37-49
- Surgical treatment of solitary adrenal metastasis from non-small cell lung cancer.J Thorac Cardiovasc Surg. 2005; 130: 136-140
- Oligometastases and oligo-recurrence: the new era of cancer therapy.Jpn J Clin Oncol. 2010; 40: 107-111
- Stereotactic body radiotherapy for oligoprogressive cancer.Br J Radiol. 2016; 89: 20160251
- The distribution of secondary growths in cancer of the breast. 1889.Cancer Metastasis Rev. 1989; 8: 98-101
- The organ microenvironment and cancer metastasis.Differentiation. 2002; 70: 498-505
- Hypoxia-induced dedifferentiation of tumor cells–a mechanism behind heterogeneity and aggressiveness of solid tumors.Semin Cell Dev Biol. 2005; 16: 554-563
- Molecular basis of metastasis.N Engl J Med. 2008; 359: 2814-2823
- Cancer metastasis: building a framework.Cell. 2006; 127: 679-695
- Genetic determinants of cancer metastasis.Nat Rev Genet. 2007; 8: 341-352
- The preclinical natural history of serous ovarian cancer: defining the target for early detection.PLoS Med. 2009; 6: e1000114
- Distant metastasis occurs late during the genetic evolution of pancreatic cancer.Nature. 2010; 467: 1114-1117
- Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97.World J Gastroenterol. 2001; 7: 630-636
- Establishment of cell lines with high- and low-metastatic potential from PC-14 human lung adenocarcinoma.Jpn J Cancer Res. 2001; 92: 174-183
- The evolutionary history of lethal metastatic prostate cancer.Nature. 2015; 520: 353-357
- Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: a multi-institutional pooled analysis.PLoS One. 2018; 13: e0195149
- Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial.J Clin Oncol. 2018; 36: 446-453
- An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer.Clin Lung Cancer. 2014; 15: 346-355
- Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs.PLoS One. 2012; 7: e50141
- MicroRNA expression characterizes oligometastasis(es).PLoS One. 2011; 6: e28650
- 14q32-encoded microRNAs mediate an oligometastatic phenotype.Oncotarget. 2015; 6: 3540-3552
- DNA methylation controls metastasis-suppressive 14q32-encoded miRNAs.Cancer Res. 2019; 79: 650-662
- Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal.Cell. 2018; 173: 581-594.e12
- Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis.Nat Commun. 2018; 9: 1793
- Molecular classification of lymph node metastases subtypes predict for survival in head and neck cancer.Clin Cancer Res. 2019; 25: 1795-1808
- Integrated molecular and clinical staging defines the spectrum of metastatic cancer.Nat Rev Clin Oncol. 2019; 16: 581-588
- Benchmark Credentialing results for NRG-BR001: the first National cancer Institute-Sponsored trial of stereotactic body radiation therapy for multiple metastases.Int J Radiat Oncol Biol Phys. 2017; 97: 155-163
- Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.Lancet Oncol. 2016; 17: 1672-1682
- Local consolidative therapy Vs. Maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study.J Clin Oncol. 2019; 37: 1558-1565
- Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial.JAMA Oncol. 2018; 4: e173501
- Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.Lancet. 2019; 393: 2051-2058
- Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.Lancet. 2018; 392: 2353-2366
- Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial.Eur Urol. 2019; 75: 410-418
- Randomized phase II study of pembrolizumab after stereotactic body radiotherapy (SBRT) versus pembrolizumab alone in patients with advanced non-small cell lung cancer: the PEMBRO-RT study.J Clin Oncol. 2018; 36: 9023
- A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC).J Clin Oncol. 2018; 36: 6009
- Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors.J Clin Oncol. 2018; 36: 1611-1618
- Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.Lancet. 2019; 393: 40-50
- Sorafenib in advanced hepatocellular carcinoma.N Engl J Med. 2008; 359: 378-390
- High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy.Int J Radiat Oncol Biol Phys. 2001; 50: 287-293
- Detection of oligoprogressive disease in oncogene-addicted non-small cell lung cancer using PET/CT versus CT in patients receiving a tyrosine kinase inhibitor.Lung Cancer. 2018; 126: 112-118
- Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG oncology/RTOG 0813 trial.J Clin Oncol. 2019; 37: 1316-1325
- INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy.J Clin Oncol. 2002; 20: 1167-1174
- Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.Lancet Oncol. 2015; 16: 187-199
Article info
Publication history
Published online: October 28, 2019
Footnotes
Disclosure Statement: The authors have nothing to disclose.
Identification
Copyright
© 2019 Elsevier Inc. All rights reserved.
